What is L-Carnitine?
L-carnitine (levocarnitine) is a quaternary ammonium compound derived from the amino acids lysine and methionine, synthesized endogenously in the liver and kidneys. It is also obtained through the diet, primarily from red meat and dairy products.
It is not a peptide in the strict sense, but shares the administration profile and mechanisms of action of research compounds used in contexts of metabolic optimization and body composition improvement.
L-carnitine was identified in meat muscle in the early 20th century (hence its name, from Latin carnis, meat). Its biological function was elucidated decades later: it acts as an obligatory transporter of long-chain fatty acids across the inner mitochondrial membrane — the necessary step that allows those fatty acids to be oxidized to produce ATP.
Mechanism of Action: The Mitochondrial Transporter
CPT1/CPT2 System — The Carnitine Shuttle
Long-chain fatty acids (>12 carbons) cannot cross the inner mitochondrial membrane on their own. The process requires a three-step active transport system:
- At the outer mitochondrial membrane: The enzyme carnitine palmitoyltransferase 1 (CPT1) links the activated fatty acid (acyl-CoA) with free carnitine, forming acylcarnitine.
- Across the membrane: The carnitine-acylcarnitine translocase (CACT) transports acylcarnitine into the mitochondrial interior, exchanging free carnitine back to the outside.
- In the mitochondrial matrix: Carnitine palmitoyltransferase 2 (CPT2) releases the fatty acid from carnitine, regenerating acyl-CoA for beta-oxidation.
Without sufficient carnitine, fatty acids cannot enter the mitochondria. They accumulate in the cytosol, blocking their use as fuel.
Free Acyl-CoA Buffer
L-carnitine also acts as a regulatory buffer for the free acyl-CoA / free CoA ratio within the mitochondria. An excess of free acyl-CoA impairs multiple mitochondrial enzymatic pathways. Carnitine “frees” the CoA pool by forming exportable acylcarnitines, maintaining the efficient operation of energy metabolism.
Why Subcutaneous Route?
Oral Bioavailability: Only 5-18%
Oral L-carnitine absorption is limited by two mechanisms:
- Saturated intestinal transport: The OCTN2 transporters in the small intestine are easily saturated, limiting maximum absorption.
- Microbiota degradation: A significant fraction of oral carnitine is metabolized by specific intestinal bacteria (Clostridium sporogenes, Peptostreptococcus spp.) into trimethylamine (TMA), which the liver oxidizes to TMAO (trimethylamine N-oxide).
The TMAO Problem
TMAO is a proatherogenic metabolite: observational studies (Koeth et al., Nature Medicine 2013) associate elevated plasma TMAO levels with higher cardiovascular risk, including atherosclerosis. This association raises debate about the long-term safety of oral L-carnitine supplementation, particularly at high doses.
The SC Route Advantage
- ~100% bioavailability: Subcutaneous absorption completely bypasses the intestine, avoiding both microbiota degradation and transporter saturation.
- No intestinal TMAO production: Without passing through the GI tract, there is no substrate for bacterial conversion.
- More predictable and consistent plasma levels.
This distinction is especially relevant for people with pro-inflammatory intestinal microbiota or elevated baseline cardiovascular risk.
Reported Protocol (SC Use)
Reconstitution: 200 mg in 2.0 mL bacteriostatic water → 100 mg/mL Equivalence: 1 U-100 unit = 1 mg
| Phase | Daily Dose | SC Volume | U-100 Units | Duration |
|---|---|---|---|---|
| Starter | 50 mg | 0.50 mL | 50 u | Weeks 1–2 |
| Maintenance | 100 mg | 1.00 mL | 100 u | Weeks 3–12 |
| Advanced | 200 mg | 2.00 mL | 200 u | Per tolerance |
Recommended timing:
- AM fasted or 30-60 minutes pre-exercise to maximize L-carnitine availability during the period of highest beta-oxidation demand.
- Avoid late evening administration: increased mitochondrial energy production efficiency may interfere with falling asleep.
Storage
- Lyophilized (powder): ≤–20°C, protected from light.
- Reconstituted: 2–8°C, use within 28 days.
- Do not refreeze once reconstituted — unlike some peptides, reconstituted L-carnitine does not tolerate freeze-thaw cycles well.
- The solution should be clear and colorless; discard if turbidity appears.
Effects and Investigated Applications
Body Composition
A 2016 meta-analysis (Pooyandjoo et al., Obesity Reviews) including 9 controlled trials found that L-carnitine supplementation produced a statistically significant reduction in body weight and BMI versus placebo, with a more pronounced effect in obese individuals and in longer-duration studies.
The SC route, providing greater bioavailability than oral, is expected to amplify these effects.
Fatigue and Physical Performance
Carnitine is essential for muscle metabolism during endurance exercise. Suboptimal muscle carnitine levels are associated with:
- Higher lactate production during intense exercise
- Greater reliance on glycogen vs. fat as fuel
- Earlier muscle fatigue and slower recovery
L-carnitine supplementation in human muscle models has demonstrated reduced glycogen utilization, increased fat oxidation rates, and reduced lactate production at submaximal intensities.
Cardiovascular Support
Carnitine is critical for cardiac energy metabolism, which depends ~70% on fatty acid oxidation. In myocardial ischemia, free carnitine levels fall dramatically. Studies of IV L-carnitine in myocardial infarction and dilated cardiomyopathy have shown improvements in ejection fraction and event reduction.
Male Fertility
There is clinical evidence that L-carnitine (particularly L-acetylcarnitine) improves sperm motility and morphology in men with oligoasthenozoospermia. The epididymis has the highest concentration of free carnitine in the entire body.
Adverse Effects
Subcutaneous L-carnitine is well tolerated in the vast majority of users:
- Fishy body odor / sweating: TMAO metabolite and TMA (though in lesser quantity via SC than oral) can produce a characteristic fishy odor in perspiration and breath, especially at high doses. More common in individuals with specific intestinal flora.
- Insomnia or difficulty sleeping: If administered in the afternoon/evening, increased mitochondrial metabolic efficiency may interfere with sleep onset.
- Mild nausea: Occasional, especially at the beginning of the protocol.
- Mild agitation or nervousness: Reported at very high doses (>500 mg/day), related to metabolic stimulation.
- Contraindications: Untreated hypothyroidism (may interfere with thyroxine metabolism); active seizures (L-carnitine may lower seizure threshold in some reported cases with very high doses).
This content is for educational purposes only. Not medical advice. Always consult a healthcare professional.
Reported protocol (research reference)
| Vial sizes | 200 mg |
|---|---|
| Reported dose | 50 mg/day SC weeks 1-2. 100 mg/day weeks 3-12. Advanced: up to 200 mg/day. Administer AM or pre-workout. Reconstitution: 200 mg in 2.0 mL BAC water → 100 mg/mL (1 U-100 unit = 1 mg). |
| Half-life | ~17 hours in plasma; shorter distribution half-life (~2-4h). |
| FDA status | FDA approved |